Chemotherapy for metastatic breast cancer.
作者： Laura Biganzoli , Alessandro Minisini , Matti Aapro , Angelo Di Leo
DOI: 10.1097/00001703-200402000-00008
关键词: Trastuzumab 、 Population 、 Taxane 、 Chemotherapy 、 Randomized controlled trial 、 Metastatic breast cancer 、 Cancer 、 Internal medicine 、 Oncology 、 Anthracycline 、 Medicine
摘要: PURPOSE OF REVIEW This review is intended to summarize the most up-to-date information in field of chemotherapy for advanced breast cancer. RECENT FINDINGS During past year, literature on metastatic cancer has focused three main areas interest: development new cytotoxic agents with studies addressing taxane-pretreated population; evaluation combination regimens, mainly incorporating a taxane; and trastuzumab-cytotoxic-agent combinations HER-2-positive population. In addition, interesting data regarding versus sequential single-agent optimal duration have been published. SUMMARY Interesting drugs faced phase II development. Randomized trials will define their role daily management New generally taxane, improve short-term efficacy comparison standard anthracycline-based or chemotherapy, but at cost increased toxicity. Trastuzumab can be safely combined several agents.
sci-hub.se 参考文章(15)
M.A Nooij, J.C.J.M de Haes, L.V.A.M Beex, J Wildiers, J Klijn, D Becquart, J Jassem, E Engelsman, L Duchateau, Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences. European Journal of Cancer. ,vol. 39, pp. 614- 621 ,(2003) , 10.1016/S0959-8049(02)00869-9
Hervé Curé, Sophie Amat, Frédérique Penault-Llorca, Guillaume le Bouëdec, Jean-Pierre Ferrière, Marie-Ange Mouret-Reynier, Fabrice Kwiatkowski, Viviane Feillel, Jacques Dauplat, Philippe Chollet, Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy Breast Cancer Research and Treatment. ,vol. 76, pp. 37- 45 ,(2002) , 10.1023/A:1020274709327
M. Bontenbal, J.J. Braun, G.J. Creemers, A.C. de Boer, J.Th.P. Janssen, M.B.L. Leys, K.L.C. Schothorst, P.I.M. Schmitz, J.J. Bokma, C. Seynaeve, 671 Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC) Ejc Supplements. ,vol. 1, ,(2003) , 10.1016/S1359-6349(03)90702-6
George W. Sledge, Donna Neuberg, Patricia Bernardo, James N. Ingle, Silvana Martino, Eric K. Rowinsky, William C. Wood, Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193) Journal of Clinical Oncology. ,vol. 21, pp. 588- 592 ,(2003) , 10.1200/JCO.2003.08.013
Harold J. Burstein, Lyndsay N. Harris, P. Kelly Marcom, Rosemary Lambert-Falls, Kathleen Havlin, Beth Overmoyer, Robert J. Friedlander, Janet Gargiulo, Rochelle Strenger, Charles L. Vogel, Paula D. Ryan, Mathew J. Ellis, Raquel A. Nunes, Craig A. Bunnell, Susana M. Campos, Michele Hallor, Rebecca Gelman, Eric P. Winer, Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm Journal of Clinical Oncology. ,vol. 21, pp. 2889- 2895 ,(2003) , 10.1200/JCO.2003.02.018
J.-M. Extra, F. Cognetti, S. Chan, D. Maraninchi, R. Snyder, a. Lluch, M. Tubiana-Hulin, D. Grimes, K. Mayne, M. Marty, 672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer Ejc Supplements. ,vol. 1, ,(2003) , 10.1016/S1359-6349(03)90703-8
P. Ravdin, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower, L. Laufman, S. Sundaram, W. Urba, S. Olsen, M.L. Meyers, S. Jones, 670 Phase III comparison of docetaxel (D)and pacilitaxel (P) in patients with metastatic breast cancer (MBC) Ejc Supplements. ,vol. 1, ,(2003) , 10.1016/S1359-6349(03)90701-4
David Loesch, Nicholas Robert, Lina Asmar, Mary Ann Gregurich, Mark O’Rourke, Shaker Dakhil, Edwin Cox, Phase II Multicenter Trial of a Weekly Paclitaxel and Carboplatin Regimen in Patients With Advanced Breast Cancer Journal of Clinical Oncology. ,vol. 20, pp. 3857- 3864 ,(2002) , 10.1200/JCO.2002.08.129
Mohammad Jahanzeb, Trastuzumab-Based Combinations in Metastatic Breast Cancer: How to Make a Choice Clinical Breast Cancer. ,vol. 4, pp. 28- 38 ,(2003) , 10.3816/CBC.2003.N.009
E. Heidemann, H. Stoeger, R. Souchon, W.-D. Hirschmann, H. Bodenstein, C. Oberhoff, J.T. Fischer, M. Schulze, M. Clemens, R. Andreesen, M. Mahlke, M. König, A. Scharl, K. Fehnle, M. Kaufmann, Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial Annals of Oncology. ,vol. 13, pp. 1717- 1729 ,(2002) , 10.1093/ANNONC/MDF306